Mirtazapin Sandoz (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapin Sandoz, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as a tablet for oral use. It works by modulating norepinephrine and serotonin pathways and is indicated for the treatment of major depressive disorder in adult patients, helping to improve mood, sleep and appetite.

GNH USA supplies Mirtazapin Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing and regulatory‑aligned distribution for healthcare providers through established global networks.

Mirtazapine is a NaSSA antidepressant that acts on neurotransmitter systems involved in mood regulation. - Major depressive disorder: reduces depressive symptoms, improves mood, sleep and appetite. - Depressive episodes in bipolar disorder (adjunct therapy): helps alleviate depressive phase when combined with mood stabilizers. - Depression with comorbid anxiety: may improve both mood and anxiety symptoms.

Mirtazapine may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Drowsiness or sedation - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness - Fatigue - Nausea - Headache

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Severe hypersensitivity reactions (e.g., Stevens‑Johnson syndrome) - Suicidal thoughts or worsening depression, especially early in treatment

When prescribing mirtazapine, clinicians should consider several safety measures. - Assess psychiatric history: evaluate for suicidal ideation before initiating therapy. - Monitor weight and metabolic parameters: track changes in appetite, weight and lipid profile regularly. - Use caution in patients with hepatic impairment: dose adjustments may be required. - Avoid abrupt discontinuation: taper under medical supervision to reduce withdrawal symptoms. - Store at ambient temperature below 25°C: keep in original packaging, protect from moisture and light.

Mirtazapine can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of serotonin syndrome; a 14‑day washout is required. - Potent CYP1A2 inhibitors (e.g., fluvoxamine): may increase mirtazapine plasma concentrations. - Central nervous system depressants (e.g., benzodiazepines, alcohol): can enhance sedation and respiratory depression.

Moderate Interactions (Monitor Closely): - CYP2D6 substrates (e.g., codeine, tramadol): metabolism may be altered. - Anticholinergic agents: additive dry mouth and constipation. - Other serotonergic agents (e.g., SSRIs, SNRIs): monitor for signs of serotonin syndrome.